<?xml version="1.0" encoding="UTF-8"?>
<p id="p0240">In early 
 <italic>in vitro</italic> studies, chloroquine and hydroxychloroquine were found to inhibit SARS-CoV-2 infection efficiently,
 <xref rid="bib40" ref-type="bibr">
  <sup>40</sup>
 </xref>
 <sup>,</sup>
 <xref rid="bib44" ref-type="bibr">
  <sup>44</sup>
 </xref> and several clinical trials have been quickly conducted in China to evaluate the efficacy and safety of chloroquine and hydroxychloroquine. Gao et al. summarized that compared with the control treatment, chloroquine phosphate was effective in inhibiting the exacerbation of pneumonia, improving lung imaging findings, promoting a virus-negative conversion, and shortening the disease course.
 <xref rid="bib45" ref-type="bibr">
  <sup>45</sup>
 </xref> The expert consensus on chloroquine phosphate recommends 500 mg twice daily for 10 days for patients diagnosed with COVID-19. Adverse effects of chloroquine and hydroxychloroquine must be carefully monitored.
 <xref rid="bib46" ref-type="bibr">
  <sup>46</sup>
 </xref>
</p>
